Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More
CRISPR Therapeutics is shifting focus toward its investigational medicine CTX310, which targets high cholesterol and cardiovascular disease. While Casgevy was a breakthrough, CTX310 represents a significantly larger market opportunity.
Why it matters
The success of gene-editing therapies for common metabolic conditions could revolutionize standard cardiovascular care.
CRISPR Therapeutics ( CRSP -1.20% ) has a major claim to fame. It developed a medicine called Casgevy, which in 2023 became the first approved therapy to use the Nobel Prize-winning CRISPR gene-editing technique. Casgevy is currently CRISPR Therapeutics' only approved medicine, and it shares the rights to it with Vertex Pharmaceuticals ( VRTX -2.10% ) . This therapy is important to CRISPR Therapeutics' prospects, but the company arguably has even more critical catalysts on the horizon.
Notably, the mid-cap biotech has several promising candidates in the pipeline that could make significant progress over the next few years. Let's discuss one of them: CTX310. Here's why this investigational medicine is, perhaps, even more important to CRISPR Therapeutics' future.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in